Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand NM Ferguson, D Laydon, G Nedjati-Gilani, N Imai, K Ainslie, M Baguelin, ... Imperial College London, 2020 | 4961 | 2020 |
Estimates of the severity of coronavirus disease 2019: a model-based analysis R Verity, LC Okell, I Dorigatti, P Winskill, C Whittaker, N Imai, ... The Lancet infectious diseases 20 (6), 669-677, 2020 | 4386 | 2020 |
Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe S Flaxman, S Mishra, A Gandy, HJT Unwin, TA Mellan, H Coupland, ... Nature 584 (7820), 257-261, 2020 | 3948 | 2020 |
Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ... Nature 593 (7858), 266-269, 2021 | 1082 | 2021 |
Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ... Cell 184 (1), 64-75. e11, 2021 | 1066 | 2021 |
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study T Nyberg, NM Ferguson, SG Nash, HH Webster, S Flaxman, N Andrews, ... The lancet 399 (10332), 1303-1312, 2022 | 1064 | 2022 |
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ... The Lancet Infectious Diseases 22 (1), 35-42, 2022 | 801 | 2022 |
Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations R Andrew Virological, 2020 | 795 | 2020 |
Probability based estimation theory for respondent driven sampling E Volz, DD Heckathorn Journal of official statistics 24 (1), 79, 2008 | 756 | 2008 |
Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ... MedRxiv, 2020.12. 30.20249034, 2021 | 609 | 2021 |
Reduction in mobility and COVID-19 transmission P Nouvellet, S Bhatia, A Cori, KEC Ainslie, M Baguelin, S Bhatt, ... Nature communications 12 (1), 1-9, 2021 | 547 | 2021 |
Viral phylodynamics EM Volz, K Koelle, T Bedford PLoS computational biology 9 (3), e1002947, 2013 | 465 | 2013 |
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7 B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ... Cell reports 35 (13), 2021 | 424 | 2021 |
SIR dynamics in random networks with heterogeneous connectivity E Volz Journal of mathematical biology 56, 293-310, 2008 | 400 | 2008 |
Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK L Du Plessis, JT McCrone, AE Zarebski, V Hill, C Ruis, B Gutierrez, ... Science 371 (6530), 708-712, 2021 | 367 | 2021 |
Susceptible–infected–recovered epidemics in dynamic contact networks E Volz, LA Meyers Proceedings of the Royal Society B: Biological Sciences 274 (1628), 2925-2934, 2007 | 341 | 2007 |
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ... The Lancet Public Health 6 (5), e335-e345, 2021 | 336 | 2021 |
Edge-based compartmental modelling for infectious disease spread JC Miller, AC Slim, EM Volz Journal of the Royal Society Interface 9 (70), 890-906, 2012 | 281 | 2012 |
Phylodynamics of infectious disease epidemics EM Volz, SL Kosakovsky Pond, MJ Ward, AJ Leigh Brown, SDW Frost Genetics 183 (4), 1421-1430, 2009 | 268 | 2009 |
Estimates of the severity of COVID-19 disease R Verity, LC Okell, I Dorigatti, P Winskill, C Whittaker, N Imai, ... MedRxiv, 2020.03. 09.20033357, 2020 | 256 | 2020 |